Combination chemotherapy with methotrexate, bleomycin and cisplatin for advanced squamous cell carcinoma of the male genital tract

F. H. Dexeus, C. J. Logothetis, A. Sella, R. Amato, R. Kilbourn, K. Fitz, A. Striegel

Research output: Contribution to journalArticlepeer-review

Abstract

A total of 14 men with inoperable or metastatic squamous cell carcinoma of the genital tract received methotrexate, bleomycin and cisplatin. In 12 patients the penis was the primary site. Metastases were usually advanced, and 4 patients had ulceration and infection in the inguinal region or perineum secondary to tumor. Two patients had tumor-related hypercalcemia. Of the patients 11 received the 3 drugs intravenously, whereas 3 received methotrexate intravenously, and bleomycin and cisplatin intra-arterially for large unilateral nodal metastasis. Of the 14 patients 10 responded, for a response rate of 72% (95% confidence interval 57 to 92%) and the median response duration was 6 months (range 4 to 24 months). Two patients (14%) who were treated intravenously achieved complete responses lasting 6 and 24+ months. Responses occurred in 3 patients with infection and in both patients with hypercalcemia. The combination of methotrexate, bleomycin and cisplatin has significant activity in patients with advanced squamous cell carcinoma of the male genital tract. This chemotherapy regimen should be evaluated in earlier disease in the adjuvant or neoadjuvant setting.

Original languageEnglish
Pages (from-to)1284-1287
Number of pages4
JournalJournal of Urology
Volume146
Issue number5
DOIs
StatePublished - 1991
Externally publishedYes

Keywords

  • Bleomycin
  • Carcinoma
  • Cisplatin
  • Methotrexate
  • Penile neoplasms
  • Squamous cell

Fingerprint

Dive into the research topics of 'Combination chemotherapy with methotrexate, bleomycin and cisplatin for advanced squamous cell carcinoma of the male genital tract'. Together they form a unique fingerprint.

Cite this